Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C

Algeron (cepeginterferon alfa-2b) is a new pegylated form of interferon alfa containing linear polyethylene glycol (molecular weight 20 kDa). Pharmacokinetic profile of Algeron allows once weekly administration. In phase II–III study 150 treatment-naive patients with compensated liver function were...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. O. Znoyko, M. V. Maevskaya, E. A. Klimova, S. L. Maksimov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya
Format:	Article
Language:	Russian
Published:	Journal Infectology 2014-09-01
Series:	Журнал инфектологии
Subjects:	chronic hepatitis c treatment early virologic response pegylated interferon alfa cepeginterferon alfa-2b algeron
Online Access:	https://journal.niidi.ru/jofin/article/view/158
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice
by: N. P. Blokhina, et al.
Published: (2016-07-01)

Efficacy and safety of сepeginterferon alfa-2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice
by: A. I. Pavlov, et al.
Published: (2016-11-01)

EFFICACY AND SAFETY OF THE COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON ALFA-2A IN PATIENTS WITH CHRONIC HEPATITIS C: THE RESULTS OF TWO MULTICENTER, PROSPECTIVE, OPEN, NON-COMPARATIVE CLINICAL TRIALS
by: K. V. Zhdanov, et al.
Published: (2018-01-01)

Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C
by: Jorge Luis Sandoval-Ramirez, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies
by: K. A. Perova, et al.
Published: (2022-04-01)

Successful desensitization protocol to alglucosidase and avalglucosidase alfa in a patient with infantile-onset Pompe disease
by: Miriam Gendive, et al.
Published: (2025-06-01)

PET imaging of differentiated thyroid cancer with thyrotropin-alfa
by: Grayson R. Gimblet, et al.
Published: (2025-04-01)

Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies
by: Fatma Al Jasmi, et al.
Published: (2025-03-01)

Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022
by: D. G. Shchurov, et al.
Published: (2023-04-01)

Effects of asfotase alfa on fracture healing of adult patient with hypophosphatasia and literature review
by: Songqi Wang, et al.
Published: (2025-04-01)

Autoimmune manifestation of hepatitis C virus infection as a risk for late virological relapse after pegylated interferon and ribavirin therapy
by: Ružić Maja, et al.
Published: (2018-01-01)

Study of Serum Protein Profiles in Burn Patients
by: Dr. R.K. Mahajan, et al.
Published: (1993-04-01)

Lactoferrin acute-phase protein and proteinase inhibitors in blood of patients with Q-wave myocardial infraction complicated by acute heart failure
by: K. P. Belokoneva, et al.
Published: (2012-06-01)

Complex treatment of allergic eye diseases using interferon alfa-2b and loratadine gel for topical and external use
by: A. V. Surov,, et al.
Published: (2014-07-01)

Use of dornase alfa in the management of life-threatening mucostasis in airway stents: its efficacy and safety
by: Demet Turan, et al.
Published: (2025-02-01)

EFFECTIVENESS AND SAFETY OF VELAGLUCERASE ALFA IN TREATMENT OF GAUCHER DISEASE TYPE 1 (ACCORDING TO INTERNATIONAL STUDIES)
by: O. S. Gundobina, et al.
Published: (2014-11-01)

Major results of a phase III comparative multicenter study on the follitropin alfa biosimilar (Primapur®) and the original follitropin alfa (Gonal-f®)
by: Z. B. Barakhoeva, et al.
Published: (2018-11-01)

Clinical Outcomes in Patients Receiving Originator Follitropin Alfa and Follitropin Alfa Biosimilars in Real-world Clinical Practice: A Retrospective Study
by: Nayana Hitesh Patel, et al.
Published: (2023-04-01)

Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)
by: Ilaria Ammendolia, et al.
Published: (2024-11-01)

Effects of carvacrol, alfa pinene and cineole-rich essential oil mixed on performance, egg production and quality and egg lipid peroxidation in laying quails
by: Aziz Bulbul, et al.

Efficacy and safety of pegylated-interferon alpha therapy in patients with chronic hepatitis B in recource-limited settings- Serbian single-center experience
by: Bojović Ksenija, et al.
Published: (2020-01-01)

The effectiveness of the use of the drug recombinant interferon alfa-2b for the prevention of acute respiratory infections in preschool children
by: S. A. Drakina, et al.
Published: (2019-12-01)

Single-chain recombinant clotting factor VIII (lonoctocog alfa): clinical experience in Russia
by: M. V. Kosinova
Published: (2022-02-01)

Variaciones de alfa-amilasa salival relacionadas con edad, sexo e índice de masa corporal en estudiantes universitarios
by: Rolando Pablo Alejandro Juárez, et al.
Published: (2024-03-01)

PENGARUH SUPLEMENTASI ALFA TOKOFEROL TERHADAP STOMATITIS TERKAIT KEMOTERAPI PADA PENDERITA KANKER PAYUDARA INVASIF
by: Bernardus Ryan Hartanto, et al.
Published: (2017-06-01)

NEW APPROACHES TO THERAPY OF CLASSICAL PH-NEGATIVE MYELOPROLIFERATIVE DISEASES: THE EXPERIENCE OF EARLY THERAPY WITH CEPEGINTERFERON ALPHA-2B
by: A. S. Polyakov, et al.
Published: (2018-05-01)

Experimental and Numerical Analyses of Alfa/Polyester Composite Under Three-Point Bending
by: Mokhtar Belkacem, et al.
Published: (2025-04-01)

L'alfa (Stipa tenacissima L.) dans la plaine de Midelt (haut bassin versant de la Moulouya, Maroc) – Éléments de climatologie
by: Mustapha Rhanem
Published: (2009-01-01)

Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa
by: Angela Schulz, et al.
Published: (2025-03-01)

DEVELOPMENT OF A QUALIFICATION PROCEDURE FOR METHIONINE FORM OF INTERFERON ALFA-2b STANDARD TO CONFIRM ITS AUTHENTICITY BY MEANS OF A PEPTIDE MAPPING METHOD
by: O. B. Ustinnikova, et al.
Published: (2018-06-01)

Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson’s disease patients
by: Gabriela S. Longo, et al.
Published: (2015-06-01)

De alfa a omega: Estimación de la confiabilidad ordinal. Una guía práctica
by: Nicolás Vizioli, et al.
Published: (2022-12-01)

Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation
by: Bo-Wen Zhuang, et al.
Published: (2022-12-01)

Alfa-mannosidosis: Frequent Symptoms in Rare Patient
by: Nato D. Vashakmadze, et al.
Published: (2023-01-01)

A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database
by: Yunlin Yang, et al.
Published: (2025-04-01)

Cipaglucosidase alfa and miglustat for treatment of late-onset Pompe disease (LOPD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
by: Elizabeth K. Baker, et al.
Published: (2025-01-01)

Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy
by: Uma Ramaswami, et al.
Published: (2025-06-01)

Corifollitropin Alfa Compared to Daily Recombinant FSH in in Vitro Fertilization Programmes: A Meta-Analysis of Randomized-Controlled Trials
by: Maria Cristina Budani, et al.
Published: (2023-02-01)

Case Report: Suboptimal response to standard-dose asfotase alfa in perinatal hypophosphatasia indicates a need for individualized dosing
by: Danijela Petković Ramadža, et al.
Published: (2025-06-01)